

2018



# Progetto Ematologia Romagna

## ***La diagnostica dell'inflammazione***

Lucia Catani

# Inflammation


**Meccanismo protettivo** in risposta a danno tissutale dovuto a infezioni, trauma, agenti chimici



**citochine infiammatorie**




I granulociti neutrofili sono le prime cellule a raggiungere il sito infiammatorio seguendo il gradiente di **citochine infiammatorie**;  
Infiltrato immune di linfociti e macrofagi




2018

## Tipica risposta infiammatoria:

- 1) Induttori infiammazione
- 2) Sensori infiammazione
- 3) Mediatori dell' infiammazione
- 4) Tessuto target





2018

# **Inflammation/Inflammazioni?**

## Tipo infezione:

Batteri  
Virus  
Parassiti


Sensori  
Mediatori  
Tessuto target


↓  
differenti

↓  
appropriata risposta infiammatoria





# INDUTTORI DELL' INFIAMMAZIONE





**Figure 2. Initiation of Prolonged Inflammation Usually Requires Signals from Both Microbes and Injured Tissue**






# INFIAMMAZIONE CRONICA



**Figure 1.** Mechanisms, anatomical locations, and disease types involving chronic inflammation. Chronic inflammation can be initiated by autoantigens or in response to damage associated molecular patterns (DAMPs). Furthermore, the microbiota – via the action of their metabolites, etc. – as well as the aging process itself have been shown to be involved in certain types of chronic inflammation.

Bioessays 37: 1005–1015, © 2015 The Authors. BioEssays published by WILEY Periodicals, Inc.



2018

# **Biomarkers infiammatori, quale/i dovrebbe(ro) essere raccomandato/i?**



# Citochine


Molecole di segnale coinvolte nell' infiammazione e sintetizzate in risposta a stimoli del microambiente


Classicamente in 2 classi:

Citochine anti-infiammatorie: IL-4, IL-10, IL-13, TGF- $\beta$

Citochine infiammatorie: IL-1 $\beta$ , IL-6, IL-15, IL-17, IL-23; TNF- $\alpha$


*“signalling intracellulare”*: NF-KB/MAPK/JAK-STAT







2018



# Proteina C reattiva



**Marker di infiammazione non specifico:  
aumento in risposta a danno tissutale, infezione, infiammazione**



**Sintetizzata dal fegato in risposta ad elevati livelli di **IL-6**, **IL-1** e **TNF****



**Ha un' emivita di circa 19 ore in circolo**



**Valore predittivo eventi cardiovascolari**







Figure 1 Pentameric structure of CRP.<sup>27</sup>

**pCRP/mCRP**

Ruolo distinto nel processo infiammatorio

pCRP ruolo anti-infiammatorio  
mCRP ruolo pro-infiammatorio



# Proteina C reattiva



**Ruolo principale: attivazione C1q con opsonizzazione patogeno/  
ruolo protettivo contro le infezioni batteriche/livelli circolanti  
Non distinguono tipo di infezione**




**Non solo marker di infiammazione ma ruolo attivo nell' infiammazione:  
Legame a recettori Fc con induzione rilascio citochine infiammatorie**



**Ruolo nell' apoptosi: produzione citochine pro-apoptotiche/  
promuove opsonizzazione cellule apoptotiche e fagocitosi**



**NON SOLO MARKER INFIAMMAZIONE/INFEZIONE  
IMPORTANTE REGOLATORE INFIAMMAZIONE**







## Measurement of CRP

Standard and high sensitivity assays:

Traditional CRP assay, using a polyclonal antibody, assists in the diagnosis and assessment of acute inflammation, i.e., associated with infections and neoplastic diseases.

A more sensitive CRP test, the highly sensitive CRP assay, allows detection of CRP levels down to and below 3 mg/L. These lower levels reflect low-grade inflammation and have a predictive value of future risk for CVD events.

The relative cardiovascular risk categories for average hs-CRP levels are:

-  low risk <1.0 mg/L
-  average risk 1.0–3.0 mg/L
-  high risk 3.0–10.0 mg/L
-  unspecific elevation >10 mg/L (should be reevaluated for acute inflammatory conditions)

## CRP / High sensitivity-CRP (hs-CRP) assays

F. Lussana, A. Rambaldi / *Journal of Autoimmunity* 85 (2017) 58–63

61


**Table 1**  
Acute phase inflammatory proteins and outcomes of MPN.

Author	Setting	Total patients	Biomarkers	Main results
Barbui 2011 [56]	ET (n = 173) and PV (n = 71) patients	244	hs CRP and PTX-3	PTX-3 and hs-CRP values were significant correlated with <i>JAK2V617F</i> allele burden greater than 50%. Patients with increased levels of hs-CRP (>3 mg/L) had an increased risk of major thrombosis. Conversely, high PTX-3 levels (>4.5ng/ml) decreased the rate of thrombosis
Barbui 2013 [57]	PMF (n = 167) and post PV or ET MF (n = 17)	184	hs CRP	Higher hs-CRP levels ( $\geq 7$ mg/dl) were independently associated with shortened leukemia free survival. Also the annual incidence rate of death was increased in patients with higher levels of hs-CRP.
Lussana 2017 [58]	ET (n = 305) and PV (n = 172) patients	477	hs CRP and PTX-3	Circulating levels of PTX-3 were significantly increased in homozygous <i>JAK2V617F</i> mutation carriers compared to all the other genotypes. The risk of hematological evolution and death from any cause was significantly increased in individuals with high PTX-3 levels, while high levels of PTX3 were associated with a trend to a lower risk of thrombosis. Patients with high hs-CRP levels exhibited an increased risk of hematological evolution and death and to a lower extent also of thrombotic events
Barosi 2017 [59]	PMF	526	hs-CRP	Subjects with <i>JAK2V617F</i> mutation and an allele burden $\geq 50\%$ had an age-independent higher incidence of elevated hs-CRP level. <i>ASXL1</i> , <i>EZH2</i> sub-clonal mutations, <i>JAK2</i> 46/1 haplotype and the A3669G polymorphism of glucocorticoid receptor were not significantly associated with increased hs-CRP levels.

PMF = primary myelofibrosis; ET = essential thrombocythemia; PV = polycythemia vera; PTX-3 = pentraxin 3; hs-CRP = high sensitivity C-reactive protein.



2018



# microRNA

Reprimono espressione genica  
degradazione mRNA target/inibizione traduzione proteina

miR146a	repressore infiammazione
miR155	attivatore infiammazione
miR 181	attivatore infiammazione

miR circolanti :  
esosomi o cell free (Risc complex)

**Table 1. Selected examples of ncRNAs with roles in regulating inflammation**

Species	Type	Disease	Cell types	Targets	Reference
miR-155	miRNA	CVD, viral infection, MS, RA, SLE, tumor immunity, chronic low-grade inflammation	Tfh, Th17, Th1, Th2, Macs, B cells, Treg, DCs	SHIP1, SOCS1, BACH1, PU.1, JARID2, PELI1, FOSI2, ETS1	[62, 63, 66–70, 77–79, 88, 106–108]
miR-146a	miRNA	Autoimmunity, dermatitis, chronic low-grade inflammation	Th1, Tfh, Treg, B cell, Macs, DCs, HSC	TRAF6, IRAK1, STAT1	[61, 68, 86, 89, 108, 109]
miR-17~92	miRNA	Tumor immunity asthma, MS, viral infection	Tfh, Th17, Th1, Th2, Treg, B cell	PTEN, PHLPP2, SOCS1, RORA, A20, IKZF4	[65, 80–82, 110, 111]
miR-181a	miRNA	Autoimmunity, aging-related inflammation	T cells	DUSP6, SHP2, DUSP5, PTPN22	[64, 112]
miR-182	miRNA	Tissue inflammation	T cells	FOXO1	[113]
miR-29a	miRNA	Crohn's disease	Th1, DC	TBET, EOMES, IL-12p40	[114, 115]
miR-125	miRNA	IBD, SLE	Macs	KLF13, IRF4	[71, 72]
miR-223	miRNA	Inflammatory lung pathology	Macs, granulocytes	Mef2c, Pknox1	[73, 74]
miR-124	miRNA	Neuro-inflammatory	Microglia	C/EBP- $\alpha$ , PU.1	[116]
LincRNA-Cox2	LncRNA	–	Macs	CCL5, IL-6	[117]
NeST	LncRNA	Microbial infection	T cells, NK cells	IFNG	[118]
LncDC	LncRNA	–	Macs	STAT3 target genes	[119]
CCR2	LncRNA	–	TH2	TH2 genes	[120]
E330013P06	LncRNA	Diabetes	Macs	–	[103]
Thrll	LncRNA	Kawasaki disease	Macs	TNF $\alpha$ , IL-8, CXCL10, CCL1, CSF1	[121]

DC, dendritic cells; HSC, hematopoietic stem cell; Macs, macrophages; NK cell, natural killer cell; Tfh, T follicular helper cells; Tregs, regulatory T cells.

# microRNA

microRNA regolano l' espressione di mRNA per citochine infiammatorie, ma anche il “signalling” citochinico ha impatto sull' espressione dei microRNA: IL-1 $\beta$  e TNF- $\alpha$  potenti stimolatori microRNA 155 e 146a

Biomarkers prognostici,

Biomarkers di conferma di un disordine

Biomarkers di risposta ad un determinato trattamento

In circolo associati a

1) Microvescicole

2) Complessi proteina/lipoproteina



## Aberrante espressione microRNA associata a disordini infiammatori/autoimmuni

microRNA







Fig. 3. Dysregulated levels of miR-125 and miR-146 in various infectious and inflammatory diseases. MiR-125 and miR-146 levels are upregulated or downregulated in various infectious and inflammatory diseases. Upper panel: up-regulated miRNA mediates chronic rhinosinusitis (CRS), Rheumatoid arthritis (RA), atopic dermatitis (AD), Myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and Hepatitis B virus infection (HBV). Lower panel: down-regulated miRNA mediates multiple sclerosis (MS), systemic lupus erythematosus (SLE), experimental autoimmune encephalomyelitis (EAE), systemic lupus erythematosus (SLE), and Crohn's disease.



# Microbiota




-100 trillioni di microbi nel corpo umano

-Immensa diversità filogenetica


-2 Phyla: Firmicutes e Bacteroidetes

-Elevata plasticità (dieta/farmaci/età)

-Funzione principale:  
immunomodulazione



## Sample collection



- Small and large intestine
- Cecum
- Feces




Figure 2. Overview of culture-independent methods for microbial analysis

High-throughput analysis of gastrointestinal tract microbiota via sequencing of DNA using targeted or shotgun sequencing or using other “omics” approaches. NGS, next generation sequencing; OTU, operational taxonomic units.

## Conclusioni:

- Una infiammazione/tante infiammazioni
- PCR marker di infiammazione più studiato
- Nuovi markers (microRNA e microbiota) da validare

Giuseppe Auteri  
Nicola Vianelli  
Francesca Palandri

Daria Sollazzo  
Dorian Forte  
Martina Barone  
Marco Romano

Daniela Bartoletti  
Sofia Fatica



A REGULAR CASE-BASED SERIES ON PRACTICAL PATHOLOGY FOR GPs

### Contents:

- Acute phase proteins and inflammation
- Measurement and interpretation of CRP
- Diagnostic value of ESR
- Case studies



# Making sense of INFLAMMATORY markers

A JOIN INITIATIVE OF



Australian  
**Doctor.**